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Abstract The rate of asymptomatic amyloidosis (AL)
among patients with newly diagnosed multiple myeloma
(MM) or smoldering multiple myeloma (SMM) is un-
known. We evaluated number and clinical significance of
asymptomatic AL in consecutive MM and SMM patients,
not having recognition of symptomatic AL at the time of
their diagnostic bone marrow biopsy. Bone marrow
biopsies were stained with Congo red and considered
diagnostic for AL in case of positive Congo red staining
with apple-green birefringence. Biopsies from 144 patients
were evaluated: 77 had a diagnosis of MM and 67 of SMM.
The median age was 59 (range 26–84) years; the median
follow-up was 76 months (range 0–216). Immunoglobulin
isotypes were 96/144 (67%), IgG; 23/144 (16%), IgA; 12/
144 (8%), light chain only; 1/77 (1%), IgD; and biclonal or
indeterminate, 12/144 (8%). Fifty-eight percent (84/144)
were κ restricted. The presence of amyloid was found in
two cases (1%, 95% CI −0.6 to 3.2), one in MM, and one in
SMM group, and none had or developed signs or symptoms
suggestive of organ involvement by amyloid. Among the
142 other patients without amyloid deposition in their index
bone marrow, one (0.7%, 95% CI −0.6 to 2.0) developed
symptomatic AL after 119 months.
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Introduction
Multiple myeloma (MM), smoldering multiple myeloma
(SMM), immunoglobulin light chain amyloidosis (AL), and
monoclonal gammopathy of undetermined significance
(MGUS) represent a spectrum of plasma cells disorders
(PCDs). AL is a rare and serious disorder characterized by
the deposition of amyloid fibrils in different tissues with
more than 80% of patients dead within 2 years of diagnosis
[1, 2]
Immunoglobulin light chain amyloidosis may coexist
with any of the other PCDs [2, 3]. It has been reported that
approximately 10% of patients with AL may have MM at
the time of diagnosis [2], while only a minority will
develop delayed MM [4]. Conversely, it has been reported
that up to 30% of MM patients may have subclinical
amyloid deposits (in subcutaneous fat aspirate, bone
marrow biopsy, or biopsies of other vital organs) [5–8],
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and in up to 15% of all MM patients, a clinically overt AL
appears during the course of index MM [3, 5]).
The rate of asymptomatic amyloidosis (asymp-amyloid)
in patients with MM or SMM as well as its clinical impact
is uncertain. This topic is significant because unrecognized
AL can be associated with significant mortality and
morbidity. In the case of patients with SMM, no treatment
will be directed against the plasma cell clone, potentially
allowing for unbridled progression of the AL. Unrecog-
nized AL in patients diagnosed with MM is also significant
because of the potential for higher rates of treatment-related
morbidity and mortality in patients with occult visceral
involvement with AL. However, at the present we deal with
discordant information. Some authors found out MM-
associated asymp-amyloid in up to 26% of patients at the
time of diagnosis [8]; this was also an independent high-
risk prognostic factor for MM patients, thus suggesting
need for searching amyloid and need for aggressive
treatment. Others believe that AL deposits, even if not
rare, are clinically inconsequential and should not influence
MM therapy, so active screening is unnecessary [6, 9].
Systemic AL can be a devastating disease with an
insidious onset, and its early recognition may improve
clinical outcomes and patients’ management. The objective
of the present investigation was therefore that of evaluating
the rate of asymp-amyloid in MM and SMM patients at the
moment of first diagnostic bone marrow (BM) biopsy.
Design and methods
Patients
Study population was selected from the Mayo Clinic
Dysproteinemia database (Division of Hematology,
Rochester MN, USA) by a computerized search of the
medical records of consecutive patients with diagnosis of
MM and SM during the period January 1, 1993 to
December 31, 2003: Diagnosis was made upon criteria on
the International Myeloma Study Group [10]. All patients
with monoclonal gammopathy seen in the Dysproteinemia
Clinic are routinely screened for symptoms and signs of
amyloidosis. Congo red staining of the bone marrow is not
routinely done unless there is clinical suspicion of
amyloidosis. For the purpose of this study, the medical
records of these patients were reviewed to discern whether
there had been coexisting signs or symptoms suggestive for
symptomatic AL at the time of diagnostic BM for MM or
SMM. Permission to perform a retrospective chart review
was granted by the Institutional Review Board of the Mayo
Foundation in accordance with federal regulations.
During the same time period, there were 691 cases of AL
diagnosed at Mayo within 30 days of their initial diagnosis.
Of them, 39 (5.6%) had more than 10% bone marrow
plasmacytosis, consistent with coexisting multiple myeloma.
Of these, only 18 (46.1% of patients with >10% of BM
plasma cells) or 2.6% of the entire AL population had
symptoms consistent with myeloma, i.e., bone lesions,
anemia (Hb<11 g/dL), calcium greater than 10.5 mg/dL,
or myeloma-related kidney disease, which was defined as
a creatinine greater than 1.5 mg/dL and a 24-h urinary M-
protein to 24-h urinary total protein ratio of greater than 0.5.
Diagnosis of asymptomatic AL
Bone marrow biopsies were reviewed and examined for
Congo red staining. A patient was considered to have
amyloid if the stain was positive, and apple-green birefrin-
gence was found on polarized microscopy. Posterior
superior iliac crest was the preferred biopsy site, and the
specimens were obtained with a modified Jamshidi needle
as an outpatient procedure. Following decalcification, the
bone marrows were paraffin embedded and H&E stained,
and Congo red stained sections were reviewed by a single
author (WB). Amyloid deposits were detected by examina-
tion at 200× under polarized light. Only data from patients
with an adequate follow-up period were considered in the
final analysis. In addition, serum samples were obtained at
diagnosis to determine LDH, β2 microglobulin, albumin,
calcium, phosphorus, creatinine, and liver function tests.
Serum and urine electrophoresis and immunofixation, as
well as bone marrow aspiration and bone X-ray studies,
were taken at diagnosis.
Statistical analysis
Baseline differences between groups were assessed by the
Chi-square test (Fisher’s exact test) for categorical variables
and univariate analysis of variance (ANOVA test) or
Mann–Whitney U statistic test for parametric and nonpara-
metric analyses. Survival was estimated using the method
of Kaplan and Meier.
Results
Overall characteristics of MM and SMM patients
Of the 1,180 patients with a diagnosis of MM (959) or
SMM (221) seen at Mayo Clinic within 30 days of their
diagnosis, biopsies were available from 144 (F 59, M 84).
Among the patients evaluated, 77 had a diagnosis of MM
and 67 of SM. Characteristics of MM and SM patients at
time of diagnosis are reported in Table 1. One hundred
thirty-six (95.8%) patients had a positive serum M-spike
before diagnostic BM. Median serum M-spike at the time
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of diagnostic BM biopsy was 2.93 (range 0.6–9.5). At a
median follow-up of living patients of 76.2 months (range
0–215.9), 46 (31.9%) patients were alive, 93 (64.5%) dead,
and 5 (3.4%) lost to follow-up. The overall median survival
was 70.4 months.
At presentation, SMM patients were older, less anemic,
had higher creatinine and urine protein, but lower urine M-
spike levels than MM patients. These last patients were
more likely to have fatigue and pain, while SMM patients
had more frequently paresthesia (Table 1).
Patients with asymptomatic amyloid deposit at presentation
Amyloid was retrospectively detected in the index bone
marrow biopsy of two of the 144 cases (1.38%, 95% CI −0.6
to 3.2), one in MM, and one in SMM group, respectively. The
first (OE, female, 66 years old) was diagnosed having MM; at
presentation, she had moderate anemia (Hg 9.4 g/l), pain,
multiple fractures but not hypercalcemia, renal, or liver tests
alteration. No measurable M-spike was identified on electro-
phoresis, but there was a monoclonal kappa light chain
detectable in the serum by immunofixation. Urine protein
electrophoresis showed a total urine protein of 280 mgwith an
M-spike of 249 mg/24 h that was confirmed to be kappa light
chain. Quantitative immunoglobulins were not done. The
bonemarrow biopsy revealed plasma cells comprising 30% of
the total cellularity. Beta-2-microglobulin was elevated at
2.28 μg/mL. Cytogenetic studies by FISH did not show IGH
translocation, monosomy, or deletion 13, deletion of p53 or
trisomy 3, 7, 9, 11, 13, 15, or 17. Cytogenetics studies of BM
showed a normal karyotype (46, XX). The second patient
(RW, male, 77 years old) was diagnosed with SMM (IgG-κ).
He had a history of weight loss and severe chronic
obstructive pulmonary disease. At presentation, physical
exam did not reveal any abnormalities. The BM biopsy
revealed plasma cells up to 25% of the total cellularity;
β2-microglobulin was 1.52 μg/mL. Bone survey was
negative for metastases or myeloma. Clinical and
laboratory characteristics are listed in Table 2. After
more than 7 years of follow-up, neither of these patients
had or developed during their disease signs or symptoms
suggestive for organ involvement by amyloid.
Patients without bone marrow amyloid deposition
at presentation but subsequent systemic amyloidosis
There was one patient (RJ, male, 51 years old) who was
diagnosed having MGUS (IgG-λ) in 1992 followed by
SMM in 1993. Clinical and laboratory characteristics at
presentation are listed in Table 2. At the presentation,
physical examination was normal. He did not have
weakness, fatigue, bleeding, or increased bruising, not bone
pain, change in his voice or tongue, steatorrhea, paresthesia,
claudication, or weight loss. He developed symptomatic AL
after 72.6 months (February 1999) from initial diagnosis of
SMM. He was treated with melphalan/prednisone. At the
time of last contact in 2002, he considered himself to be in
good health.
Discussion
Rate and clinical impact of asymp-amyloid in patients with
MM or SMM is uncertain. While asymptomatic amyloid
Table 1 Baseline patients’ characteristics
Characteristics MM population (n=77) SM population (n=67)
Median months from biopsy to last follow-up (range) 65 (10.4–169.2) 64.6 (0–210)
Such fatigue (%) 13 (16.8) 5 (7.4)
Pain (%) 42 (54.5) 1 (1.5)
Paresthesia (%) 1 (1.3) 3 (4.4)
Bleeding (%) 0 1 (1.5)
Edema (%) 0 1 (1.5)
Dyspnea (%) 6 (7.8) 1 (1.5)
Median age, years (range) 55. 5 (33–70) 63 (26–84)
Hemoglobin (g/dL), median (range) 11.0 (7.6–15.3) 12.5 (7.6–14.8)
Platelets (×109/L), median (range) 222.0 (8–399) 224.0 (65–786)
Serum protein (g/dL), median (range) 8.0 (6–16.1) 8.4 (6.3–11.8)
Urine protein (g/24 h) 0.13 (0.01–10.7) 0.1 (0.01–2.7)
Serum albumin, median (range) 3.64 (2.3–5.7) 3.60 (2.3–4.7)
Alkaline phosphate (U/L), median (range) 175.5 (53–1199) 155.0 (62–480)
Creatinine (mg/dL), median (range) 1.1 (0.7–2.2) 1.1 (0.9–6.6)
BM bone marrow, FU follow-up
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deposits have been reported to coexist at the time of MM
diagnosis in up to 30% of patients [1, 5], less information is
available in patients with established MM or SMM who are
seen at a facility at which an extensive amyloid directed
review of systems and signs is the norm. This issue is
topical since unrecognized AL can be associated with
significant mortality and morbidity, and its early detection
could change the management of MM and SMM patients.
We found that only 1.4% of patients with retrospec-
tive Congo red staining of their bone marrow had
amyloid present on their presenting bone marrow. This
may be a limitation of the present investigation, since it
is well known that the sensitivity of bone marrow
biopsy is only about 50% in comparison to that of
abdominal fat aspirate with a sensitivity of about 80%
of confirmed amyloidosis [1, 11]. It is possible that our
approach yielded a low estimate. For example, the one
patient, whose initial bone marrow was negative for
amyloidosis but who was diagnosed with AL 6 years
later, might have had a positive fat aspirate at the time of
his earlier bone marrow; if so, he would have had very
indolent amyloidosis.
Our data, which may appear to conflict with prior
reports, would suggest that a careful amyloid-specific
review at the time of diagnosis of SMM or MM misses
only 1–2% of cases even with a 6.4 person-years of follow-
up and therefore abrogates the need to do routine amyloid
staining on all cases of SMM or MM. It also supports the
Mayo Clinic practice of having a low threshold for
amyloidosis screening if non-specific symptoms are present
in a patient with a monoclonal gammopathy.
Table 3 puts our findings into the context of prior
reports. One of the first reports addressing this question was
by Desikan et al. [6], who prospectively evaluated fat pad
aspirate and BM biopsy for amyloid deposit in a cohort of
84 MM patients. Amyloid was detected in 38% of patients;
fat pad aspirate was positive in 25% and BM in 10% of
cases and other organ sites in seven patients. MM or SMM
patients did not differ in disease characteristics, and
particularly, no λ predominance was found. The median
overall and event-free survival of the entire cohort is 66+
and 52 months respectively; the median overall (59+
months vs 66+ months, p=0.9) and event-free survival
(59+ vs 52+ months, p=0.9) were similar in cohort with
and without amyloid, respectively. These authors conclud-
ed, therefore, that although the incidence of light chain
asymptomatic AL in MM patients is high, it does not
influence the outcome of these patients treated with
autologous transplantation.
Vela-Ojeda et al. evaluated 201 consecutive patients with
de novo MM in whom a fat pad biopsy needle aspiration
(stained with Congo red) was performed [8]. Overall, 68
patients (34%) were diagnosed having concomitant AL; 16
(8%) had symptoms consistent with amyloidosis at the time
of MM diagnosis, while in 52 (25.8%), fat pad aspiration
was useful to detect incidental asymptomatic AL. The
median follow-up was 36 months (range 12–199). Among
patients without AL at the time of diagnostic BM for MM,
69% of them became symptomatic for AL after a median
follow-up of 14 months (range 6 to 30). Even excluding 16
patients with obvious symptoms of AL at diagnosis, overall
survival was worse in patients who developed late AL (13
vs 64 months of those without AL). Cox regression model
for overall survival detected three variables having inde-
pendent prognostic significance: the presence of AL (RR





Patient without amyloid deposit





Months from biopsy to last follow-up 86.4 87.6 72.6
Age (year) 66 77 51
Hg (g/dL) 9.4 13 12.3
Platelets (n×109/L) 328 201 446
Pro-thrombin time (s) 10.1 NA NA
Serum protein (g/dL) NA 7.4 6.9
Urine protein (mg/dL) 280 8 13
Serum Albumin (g/dL) 2.9 3.6 3.5
Alkaline phosphate (U/L) NA 145 152
Creatinine (mg/100 mL) 0.8 1.1 0.9
Β2-microglobulin (μg/mL) 2.28 1.56 1.5
C-reactive protein level (mg/dL) NA NA 0.59
Serum light chain isotype Kappa Kappa Lambda
Table 2 Characteristics of two
patients with detection of amy-
loid deposit at presentation and
one patient without amyloid
deposit but subsequent systemic
amyloidosis
NA not available
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0.005), and patients not achieving complete remission or
very good partial remission (RR 2.9, p<0.02). The authors
then concluded that MM-associated AL represents a poorer
prognosis of disease even in the absence of symptoms at
diagnosis, and this specific association may be considered
as an independent high-risk prognostic factor. Thus, authors
concluded that routine study of peri-umbilical fat pad tissue
should be mandatory in all patients with MM.
Petruzziello et al. (2009) evaluated retrospectively the
bone marrow smears of 166 unselected patients affected
by MM (126 at diagnosis and 40 after treatment); no
data were reported about the presence of signs or
symptoms suggestive for concomitant systemic AL [12].
All samples were stained with Congo red and studied by
transmission and birefringence microscopy. Both focal and
diffuse involvements were considered positive. Overall,
67 patients were positive for AL, and 99 were negative to
Congo red and apple-green birefringence. In particular, 51
of the 126 patients studied at diagnosis and 16 of the 40
patients with advanced disease were positive. Authors
failed to find correlations between bone marrow amyloid
deposits and immunoglobulin type, disease stage, plasma
cells percentage, hemoglobin, calcium, creatinine, albu-
min, or β2-microglobulin.
Although the main objective of our investigation was
to evaluate the rate of asymp-amyloid at the time of first
BM, we were able to look at the clinical outcome of our
cohort who had a median follow-up of 6 years. Neither
of the patients who were retrospectively found to have
amyloid in their index bone marrows developed symp-
tomatic AL, and their survival did not differ from the
other patients. Among Congo red negative patients, we
detected one (SMM patient) who developed symptomatic
AL during a follow-up of 72.6 months. He had serum 1
light chain, an isotype frequently reported in patients with
AL [13].
One potential caveat in studies looking at the detection
of asymp-amyloid relies on patients’ selection. In fact, AL
requires a high index of suspicion, and most of AL cases
are often misdiagnosed with other PCDs, mainly with MM
(The UK Myeloma Forum AL Amyloidosis Guidelines
Working Group, 2004). It is not unlikely that the true
occurrence of asymptomatic AL has been previously
overestimated. Because of the high level of suspicion for
amyloid at our Amyloid Center, we are confident that all
patients evaluated did not have (even subclinical) AL at the
time of diagnostic BM for MM or SM. Therefore,
evaluation of adequate specimens in experienced laborato-
ries is necessary to maintain high diagnostic sensitivity and
specificity.
In conclusion, we evaluated rates and clinical signifi-
cance of amyloid deposit at the time of first diagnostic BM
biopsy in newly diagnosed MM and SMM. Our findings
show that fewer than 2% of patients in both groups have
asymp-amyloid, thus discouraging any specific search for
amyloid deposit when careful evaluation of clinical presen-
tation and patient’s history are not suggestive for systemic
AL.









Tissues stained for amyloid Prognostic
factor
MM cases with incidental amyloidosis
Desikan
[6]
84 32 (30.8) Subcutaneous abdominal fat
aspirate (SAFA) in 25, bone
marrow in 8, and other organ




201 68 (34)a SAFA Yes
Petruziello
[12]





77 1 (1.3) Bone marrow No
Present study
SMM
67 1 (1.5) Bone marrow No




AL cases with symptomatic MM
Rajkumar
[4]
1,596 6 (0.3) Biopsy-proven AL No laboratory or clinical evidence of MM
at the diagnosis of AL. MM developed
10–81 months hereafter
a Sixteen were symptomatic for AL
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